Biochemical and Biophysical Research Communications · 2022 · 17 citations · 28 references
MedicineCancer BiologyCell BiologyStem Cell BiologyTumor MicroenvironmentTumor ProgressionCancer Cell SignalingCancer Stem Cell BiologyCancer Stem CellsCancer TranscriptomicsSignal Transduction In CancerStem Cell TumorigenicityCancer Stem Cell - Mediated ResistanceCancer Stem Cell Response To RadiationCancer Stem Cell SurvivalCancer Stem Cell-mediated ResistanceFibronectin Type Iii DomainsMessenger Rna (Mrna) ProfilingNeoadjuvant ChemoradiationTherapy-resistant Cancer Stem Cells
Neoadjuvant chemoradiation (nCRT) followed by radical surgery is the preferred option for locally advanced colorectal cancer (CRC) treatment. However, chemo/radio-resistance remains a main obstacle in CRC therapy. In the study, we analyzed the mRNA expression profiling of CRC patients and revealed that the aberrant expression of fibronectin type III domain containing 1 (FNDC1) was associated with disease progression and poor prognosis in CRC. FNDC1 expression was consistently increased in multiple independent cohorts of CRC. Upregulated FNDC1 in pretreated primary tumor tissues predicted a poor response to nCRT, recurrence, and poor disease-free survival in nCRT-treated CRC patients. FNDC1 overexpression accelerated CRC cell survival on 5-FU or radiation treatment both in vitro and in vivo, whereas FNDC1 inhibition sensitized CRC cells to chemoradiation. In addition, FNDC1 accelerated stem cell-like properties of CRC cells. Furthermore, tumor tissues from non-responders exhibited higher activation of PI3K/Akt signaling than those from responders. FNDC1 depletion repressed 5-FU or irradiation-induced activation of PI3K/AKT in CRC cells. More importantly, pharmacological inhibition of PI3K/Akt signaling effectively decreased the effect of FNDC1 on chemoradiation resistance. Taken together, our study reveals the potential function of FNDC1 as a biomarker to predict nCRT sensitivity in CRC and a therapeutic target in CRC treatment.
28
The Human Genome Browser at UCSC
W. James Kent, Charles W. Sugnet, Terrence S. Furey et al. · Genome Research · 2002 · 10.9K citations · Full text
Targeting PI3K/Akt/mTOR Signaling in Cancer
Camillo Porta, Chiara Paglino, Alessandra Mosca · Frontiers in Oncology · 2014 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy
Mechthild Krause, Ala Yaromina, Wolfgang Eicheler et al. · Clinical Cancer Research · 2011 · 124 citations